Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 3.25 USD 9.43% Market Closed
Market Cap: 202.8m USD
Have any thoughts about
Fulcrum Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one FULC stock under the Base Case scenario is 2.49 USD. Compared to the current market price of 3.25 USD, Fulcrum Therapeutics Inc is Overvalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FULC Relative Value
Base Case
2.49 USD
Overvaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
3
Median 3Y
47.6
Median 5Y
58.2
Industry
2.5
Forward
2.5
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-7.9
Industry
21.9
Forward
-11.4
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-10
Industry
16.5
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-9.5
Industry
23.6
vs History
93
vs Industry
34
Median 3Y
2.1
Median 5Y
3.3
Industry
2.1
vs History
vs Industry
3
Median 3Y
23.6
Median 5Y
28.3
Industry
2.6
Forward
-0.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
0
vs Industry
56
Median 3Y
-2.3
Median 5Y
-4.7
Industry
13.3
Forward
2.7
vs History
0
vs Industry
53
Median 3Y
-2.2
Median 5Y
-4.5
Industry
16.6
Forward
1.9
vs History
0
vs Industry
54
Median 3Y
-2.7
Median 5Y
-6.8
Industry
15.6
vs History
0
vs Industry
40
Median 3Y
-2.6
Median 5Y
-6.1
Industry
19.1
vs History
vs Industry
6
Median 3Y
12.2
Median 5Y
28.3
Industry
1.9

Multiples Across Competitors

FULC Competitors Multiples
Fulcrum Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
202.8m USD 2.5 -11.3 2 1.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average P/E: 32.4
Negative Multiple: -11.3
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top